August 2, 2022
ROB FREEDMANEMAIL: RFREEDMAN@FENWICK.COM
DIRECT DIAL: +1 (650) 335-7292
ELEVATION ONCOLOGY, INC.
888 Seventh Ave., 12th Floor
New York, NY 10106
August 2, 2022
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Healthcare & Insurance
100 F Street, N.E.
Washington, DC 20549
Attention: | Margaret Schwartz |
Re: | Elevation Oncology, Inc. Registration Statement on Form S-3 (File No. 333-265979) filed July 1, 2022. |
Requested Date: August 4, 2022
Requested Time: 8:00 AM Eastern Time
Ladies and Gentlemen:
Elevation Oncology, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to declare the above-captioned Registration Statement on Form S-3 effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable, or at such later time as the Registrant may orally request via telephone call to the staff of the Commission.
The Registrant hereby authorizes Rob Freedman and Ryan Mitteness, both of whom are attorneys with the Registrant’s outside legal counsel, Fenwick & West LLP, to orally modify or withdraw this request for acceleration.
The Registrant requests that it be notified of such effectiveness by a telephone call to Mr. Freedman at (650) 335-7292 or, in his absence, to Mr. Mitteness at (206) 389-4533.
* * *
Sincerely,
ELEVATION ONCOLOGY, INC.
By: /s/ Shawn M. Leland
Shawn M. Leland, Pharm.D., R.Ph.
Cc | Shawn M. Leland, Pharm.D., R.Ph., Chief Executive Officer |
Joseph J. Ferra, Chief Financial Officer
Elevation Oncology, Inc.
Rob Freedman, Esq.
Ryan Mitteness, Esq.
Fenwick & West LLP
[Signature Page to Company Acceleration Request Letter]